Advertisement

Topics

San Diego's Mirati Therapeutics Abandons Lead Drug, Shifts Focus

19:00 EST 14 Nov 2017 | BioSpace

The company is reprioritizing its development programs to capitalize on encouraging data and development opportunities in its sitravatinib and KRAS programs.

Original Article: San Diego's Mirati Therapeutics Abandons Lead Drug, Shifts Focus

NEXT ARTICLE

More From BioPortfolio on "San Diego's Mirati Therapeutics Abandons Lead Drug, Shifts Focus"

Advertisement
Quick Search
Advertisement
Advertisement